Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Arguing for Better Leukemia Care

August 30th 2021

Susan M. O’Brien, MD always knew medicine was the field for her. Growing up in a house full of bankers and finance-oriented family members couldn’t deter her from her chosen path.

Emerging Strategies in the Management of Relapsed/Refractory CLL

August 30th 2021

Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.

Therapeutic Sequencing Strategies in Relapsed/Refractory CLL

August 30th 2021

Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.

Key Clinical Data in Relapsed/Refractory CLL

August 30th 2021

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

Unmet Needs in High-Risk MDS

August 27th 2021

The panel of experts highlight promising clinical trials for the treatment of myelodysplastic syndrome.

Ibrutinib Shows Continued Activity in Relapsed, Variant-Type Hairy Cell Leukemia

August 27th 2021

Ibrutinib demonstrated encouraging clinical responses in patients with variant-type, high-risk hairy cell leukemia.

Promising Data for Pevonedistat in High-Risk MDS

August 27th 2021

Amy DeZern, MD, MHS leads a discussion surrounding the mechanism of action and clinical trial data on the use of magrolimab and pevonedistat in patients with high-risk myelodysplastic syndrome.

Emerging Role of Venetoclax in the Treatment of MDS

August 27th 2021

Rami Komrokji, MD and Gail Roboz, MD, discuss treatment considerations and clinical trial data surrounding the use of venetoclax in patients with myelodysplastic syndrome or acute myeloid leukemia.

MDS Treatment: Patient Considerations

August 26th 2021

Drs Madanat and Sekeres discuss specific patient characteristics affecting selection of treatment for MDS.

MDS Treatment-Related Toxicity and AEs

August 26th 2021

Yazan Madanat, MD, explores toxicity and adverse events impacting treatment selection for patients with MDS.

The Role of Allogeneic Stem Cell Transplant in AML

August 26th 2021

Dan Pollyea, MD, MS provides a high-level overview of the role of allogeneic stem cell transplant at first remission based on risk stratification, highlighting how to select patients for transplant.

Approaches to Managing Toxicity of Venetoclax

August 26th 2021

Courtney DiNardo, MD emphasizes the importance of understanding the risk of tumor lysis syndrome, monitoring for drug-drug interactions, and performing a bone marrow biopsy at the end of cycle 1 when treating AML with venetoclax.

Roxadustat Shows Activity Against Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

August 26th 2021

The first-in-class small molecule HIF-PHI inhibitor roxadustat demonstrated promising efficacy with favorable tolerability when used in the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies, meeting the primary end point of the phase 2 WHITNEY trial.

FDA Grants Priority Review to Asciminib for Chronic Myeloid Leukemia

August 25th 2021

The FDA has granted priority review to a new drug application seeking the approval of asciminib for the treatment of patients with chronic myeloid leukemia.

Mosunetuzumab Elicits High, Durable Responses in Multiply Relapsed Follicular Lymphoma

August 24th 2021

Fixed-duration treatment with mosunetuzumab elicited encouraging responses with acceptable safety when used in patients with multiply relapsed follicular lymphoma.

Chemotherapy-Free Strategies Chart a New Course for Ph-Positive ALL

August 24th 2021

A new era for patients with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia may be on the horizon as investigative efforts aimed away from chemotherapy-based regimens prove efficacious.

Sequencing Therapies in Relapsed/Refractory ALL

August 24th 2021

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share thoughts on how to effectively sequence available treatment modalities for acute lymphocytic leukemia in various patient populations.

Salvage Therapies in R/R ALL, Including CAR T-Cell Therapy

August 24th 2021

Drs Aldoss and McKloskey describe treatments that can be used in the salvage setting of acute lymphocytic leukemia, including CAR T-cell therapy.

Frontline Therapy for CLL: Emerging Agents and Approaches

August 23rd 2021

Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.

Which Path to Take in Frontline Therapy for CLL?

August 23rd 2021

Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.